| scholarly article | Q13442814 |
| P50 | author | Akram Alian | Q55313191 |
| P2093 | author name string | Paul R Ortiz de Montellano | |
| Xin He | |||
| Robert Stroud | |||
| P2860 | cites work | A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening | Q22251350 |
| THE STRUCTURAL BIOLOGY OF TYPE II FATTY ACID BIOSYNTHESIS | Q22255655 | ||
| Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination | Q26778405 | ||
| Processing of X-ray diffraction data collected in oscillation mode | Q26778468 | ||
| Molecular basis of triclosan activity | Q27617904 | ||
| Structural basis and mechanism of enoyl reductase inhibition by triclosan | Q27618977 | ||
| Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan | Q27619680 | ||
| Inhibitor binding studies on enoyl reductase reveal conformational changes related to substrate recognition | Q27619988 | ||
| Molecular basis for triclosan activity involves a flipping loop in the active site | Q27620673 | ||
| Crystallographic analysis of triclosan bound to enoyl reductase | Q27620788 | ||
| Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data | Q27640586 | ||
| From The Cover: Automated protein crystal structure determination using ELVES | Q27643057 | ||
| Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis | Q27730411 | ||
| Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis | Q28302775 | ||
| Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium | Q28378889 | ||
| Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis | Q28487275 | ||
| The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis | Q29615201 | ||
| Databases in protein crystallography | Q29617260 | ||
| inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis | Q29617412 | ||
| A quick diversity-oriented amide-forming reaction to optimize P-subsite residues of HIV protease inhibitors | Q31106562 | ||
| A potent and highly selective inhibitor of human alpha-1,3-fucosyltransferase via click chemistry | Q33188039 | ||
| Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery | Q34090225 | ||
| Fatty acid biosynthesis as a target for novel antibacterials | Q35713880 | ||
| The reductase steps of the type II fatty acid synthase as antimicrobial targets | Q36052456 | ||
| Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility | Q41982469 | ||
| Neuroleptic activity and dopamine-uptake inhibition in 1-piperazino-3-phenylindans | Q42241923 | ||
| Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis | Q42538502 | ||
| Effect of detergent on "promiscuous" inhibitors | Q44523300 | ||
| Rapid diversity-oriented synthesis in microtiter plates for in situ screening: discovery of potent and selective alpha-fucosidase inhibitors. | Q44610505 | ||
| Roles of Tyrosine 158 and Lysine 165 in the Catalytic Mechanism of InhA, the Enoyl-ACP Reductase fromMycobacterium tuberculosis† | Q62649813 | ||
| Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru | Q73380532 | ||
| [Synthesis and vasodilative activities of benzamide derivatives] | Q74121086 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Mycobacterium tuberculosis | Q130971 |
| P304 | page(s) | 6308-6323 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis | |
| P478 | volume | 49 |
| Q27660104 | A Slow, Tight Binding Inhibitor of InhA, the Enoyl-Acyl Carrier Protein Reductase from Mycobacterium tuberculosis |
| Q28304560 | A machine learning-based method to improve docking scoring functions and its application to drug repurposing |
| Q37257884 | A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment |
| Q27339306 | A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA |
| Q35741705 | Analysis of Enoyl-Acyl Carrier Protein Reductase Structure and Interactions Yields an Efficient Virtual Screening Approach and Suggests a Potential Allosteric Site. |
| Q37034701 | Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor |
| Q34421869 | Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis |
| Q58384180 | Blocked isocyanates: an efficient tool for post-polymerization modification of polymers |
| Q47316431 | Cell wall permeability assisted virtual screening to identify potential direct InhA inhibitors of Mycobacterium tuberculosis and their biological evaluation |
| Q34150712 | Characterization of the enzymes encoded by the anthrose biosynthetic operon of Bacillus anthracis |
| Q46484201 | CoMFA based de novo design of pyrrolidine carboxamides as inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis |
| Q35878348 | Computer-Aided Design of Orally Bioavailable Pyrrolidine Carboxamide Inhibitors of Enoyl-Acyl Carrier Protein Reductase of Mycobacterium tuberculosis with Favorable Pharmacokinetic Profiles |
| Q27651378 | Design and Synthesis of Aryl Ether Inhibitors of theBacillus AnthracisEnoyl-ACP Reductase |
| Q41852593 | Design, Synthesis, Toxicity Estimation and Molecular Docking Studies of N-(furan-2-yl)-1-(5-substituted) phenyl-1,3,4-oxadiazol-2-yl) methanimine as Antitubercular Agents. |
| Q48325032 | Design, synthesis, and pharmacological evaluation of fluorinated azoles as anti-tubercular agents. |
| Q35247307 | Direct inhibitors of InhA are active against Mycobacterium tuberculosis. |
| Q33339829 | Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors |
| Q39456595 | Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach |
| Q28475676 | Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis |
| Q37886187 | Enoyl acyl carrier protein reductase inhibitors: a patent review (2006 - 2010). |
| Q51703402 | Evaluation of the inhibitory activity of (aza)isoindolinone-type compounds: toward in vitro InhA action, Mycobacterium tuberculosis growth and mycolic acid biosynthesis. |
| Q35923699 | Evolution of a thienopyrimidine antitubercular relying on medicinal chemistry and metabolomics insights. |
| Q27658743 | How Much Binding Affinity Can be Gained by Filling a Cavity? |
| Q53092961 | Identification of InhA inhibitors: A combination of virtual screening, molecular dynamics simulations and quantum chemical studies. |
| Q40531171 | Identification of Middle Chain Fatty Acyl-CoA Ligase Responsible for the Biosynthesis of 2-Alkylmalonyl-CoAs for Polyketide Extender Unit. |
| Q42930783 | Identification of novel antitubercular compounds through hybrid virtual screening approach |
| Q90171590 | Improvement of the novel inhibitor for Mycobacterium enoyl-acyl carrier protein reductase (InhA): a structure-activity relationship study of KES4 assisted by in silico structure-based drug screening |
| Q91928592 | In Silico Repositioning of Cannabigerol as a Novel Inhibitor of the Enoyl Acyl Carrier Protein (ACP) Reductase (InhA) |
| Q27647576 | Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides |
| Q39180968 | Insights into the bonding pattern for characterizing the open and closed state of the substrate-binding loop in Mycobacterium tuberculosis InhA. |
| Q39106409 | Key Structures and Interactions for Binding of Mycobacterium tuberculosis Protein Kinase B Inhibitors from Molecular Dynamics Simulation. |
| Q60998748 | Molecular dynamics of Mycobacterium tuberculosis KasA: implications for inhibitor and substrate binding and consequences for drug design |
| Q30422921 | MycPermCheck: the Mycobacterium tuberculosis permeability prediction tool for small molecules |
| Q38266496 | Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: development in the past decade. |
| Q39362128 | New structural classes of antituberculosis agents |
| Q30277026 | Outcome of the First wwPDB/CCDC/D3R Ligand Validation Workshop |
| Q34333844 | Phosphorylation of enoyl-acyl carrier protein reductase InhA impacts mycobacterial growth and survival |
| Q90132989 | Predictive Power of In Silico Approach to Evaluate Chemicals against M. tuberculosis: A Systematic Review |
| Q39203063 | Preparation of alginate-chitosan-cyclodextrin micro- and nanoparticles loaded with anti-tuberculosis compounds. |
| Q27687750 | Pyridomycin bridges the NADH- and substrate-binding pockets of the enoyl reductase InhA |
| Q47123389 | Pyrrolyl Pyrazoline Carbaldehydes as Enoyl-ACP Reductase Inhibitors: Design, Synthesis and Antitubercular Activity |
| Q38989303 | Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis |
| Q38124842 | Recent advances in inhibitors of bacterial fatty acid synthesis type II (FASII) system enzymes as potential antibacterial agents |
| Q37855895 | Recent advances in the design and synthesis of heterocycles as anti-tubercular agents |
| Q84586359 | Receptor based 3D-QSAR to identify putative binders of Mycobacterium tuberculosis Enoyl acyl carrier protein reductase |
| Q27679331 | Structural and Enzymatic Analyses Reveal the Binding Mode of a Novel Series of Francisella tularensis Enoyl Reductase (FabI) Inhibitors |
| Q90283648 | Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of Mycobacterium tuberculosis with Favorable Predicted Pharmacokinetic Profiles |
| Q42368535 | Target Identification of Mycobacterium tuberculosis Phenotypic Hits Using a Concerted Chemogenomic, Biophysical, and Structural Approach. |
| Q37979307 | Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds. |
| Q36561313 | Targeting the formation of the cell wall core of M. tuberculosis |
| Q57166319 | The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase |
| Q28476004 | The Mycobacterium tuberculosis drugome and its polypharmacological implications |
| Q58693109 | Ultrasound Assisted Synthesis of 4-(Benzyloxy)--(3-chloro-2-(substitutedphenyl)-4-oxoazetidin-1-yl) Benzamide as Challenging Anti-Tubercular Scaffold |
| Q55059617 | Validation of ligands in macromolecular structures determined by X-ray crystallography. |
Search more.